Recon: Danaher to buy Abcam for $5.7B; Novocure device flops in late-stage ovarian cancer study

• Novocure device fails in late-stage ovarian cancer trial, shares slump (Reuters) (Endpoints)
• Life sciences firm Danaher to buy Abcam in $5.7 bln deal (Reuters) (Endpoints)
• Drugmaker Mallinckrodt files for second bankruptcy in the US (Reuters)
• Weight loss drug Wegovy improves function in people with common type of heart failure (STAT)
• U.S. health officials lay out plans to cope with respiratory virus season (STAT) (Endpoints)
• FTC pauses challenge of Amgen's $28B Horizon takeover to consider settlement (Endpoints)
• FDA publishes Oncopeptides’ withdrawal appeal for Swedish biotech’s cancer drug Pepaxto (Endpoints) (Pink Sheet)
• How Fast Is ‘Expedited’? Pepaxto To Show Speed Of New Withdrawal Process For Accelerated Approval Drugs (Pink Sheet)

• Bayer says Parkinson's stem cell therapy improves symptoms in initial trial (Reuters)
• Europe to face shortage of Lilly's diabetes drug through September (Reuters)
• How Ozempic and Weight Loss Drugs Are Reshaping This Country’s Economy (NYTimes)
• Wegovy reimbursement would cost Denmark up to $4 bln each year -ministry (Reuters)
• China to drop COVID antigen test requirement for inbound travelers (Reuters)

• Verastem Oncology secures collaboration with GenFleet Therapeutics, potentially worth up to $600M+ (Endpoints)
• The ADHD drug market is already stretched thin. Now it’s facing a back-to-school supply strain (CNBC)
• Orphan drugs: small markets, large rewards (Financial Times)
• Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23 (Endpoints)
• US FDA’s New Generics Chief: We Need More Flexibility For Complex Products (Pink Sheet)
• Intarcia Gets Its Hearing: FDA Panel To Weigh Nonapproval Of Diabetes Drug/Device Combo In September (Pink Sheet)
• BridgeBio's ATTR-CM drug bests placebo in detailed PhIII data, bolstering plans for NDA (Endpoints)
• Baxter CDMO BioPharma Solutions names Franco Negron as CEO ahead of proposed sale (Endpoints)
• Pharma enters ‘age of uncertainty’ amid challenges from IRA, FTC and patent cliffs (Endpoints)
• Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer after disappointing interim results (Endpoints)

• Withings' Smart Scale Passes US FDA Test; Clearance For Detecting Atrial Fibrillation (MedtechInsight)
• GE HealthCare to bring cardiovascular-focused handheld ultrasound probe to U.S. (Fierce)
• One More IVDR Notified Body In The Wings As Designation Progress Continues To Advance (MedtechInsight)

• AstraZeneca sues US over Medicare drug price negotiation plans (Reuters) (STAT)
• Drug retailer Rite Aid prepares to file for bankruptcy, Wall Street Journal reports (Reuters)